Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00174343

Enrollment

Registered

2005-09-15

Start date

2001-11-30

Completion date

2006-09-30

Last updated

2011-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Brief summary

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Interventions

DRUGexemestane (Aromasin®)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive

Exclusion criteria

* Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative

Design outcomes

Primary

Measure	Time frame
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)	—

Secondary

Measure	Time frame
To evaluate breast conservative surgery rate; To evaluate intratumoral anti-aromatase activity.	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026